

Accepted Manuscript

BJGP OPEN

Transient elastography in patients at risk of liver fibrosis in primary care: a follow-up study over 54 months

Reinson, Tina; Byrne, Christopher; Patel, Janisha; El-Gohary, Magdy; Moore, Michael

DOI: <https://doi.org/10.3399/BJGPO.2021.0145>

To access the most recent version of this article, please click the DOI URL in the line above.

Received 05 August 2021

Revised 10 September 2021

Accepted 17 September 2021

© 2021 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License (<http://creativecommons.org/licenses/by/4.0/>). Published by BJGP Open. For editorial process and policies, see: <https://bjgpopen.org/authors/bjgp-open-editorial-process-and-policies>

When citing this article please include the DOI provided above.

Author Accepted Manuscript

This is an 'author accepted manuscript': a manuscript that has been accepted for publication in BJGP Open, but which has not yet undergone subediting, typesetting, or correction. Errors discovered and corrected during this process may materially alter the content of this manuscript, and the latest published version (the Version of Record) should be used in preference to any preceding versions

Transient elastography in patients at risk of liver fibrosis in primary care: a follow-up study over 54 months

Tina Reinson, BSc (Hons), Researcher, University of Southampton; **Christopher D Byrne**,* PhD, FRCPATH, FRCP; Professor of Endocrinology and Metabolism, University of Southampton; **Janisha Patel**, BSc, PhD, MBChB, Consultant Hepatologist, University Hospital Southampton; **Magdy El-Gohary**, BSc (hons), BM (hons), DRCOG, MRCP, MRes, General Practitioner, Shirley Health Partnership; **Michael Moore**,* BM, BS, MRCP, FRCP, Professor of Primary Health Care Research; University of Southampton

*Both authors contributed equally to the manuscript.

Address for correspondence

Tina Reinson, c/o Primary Care and Population Sciences, Room number:
0590/AHC/127/S2, Aldermoor Health Centre, Aldermoor Close, Southampton, SO16
5ST
Email: t.reinson@soton.ac.uk

Abstract

Background

Liver fibrosis assessment services using transient elastography are growing in primary care. These services identify patients requiring specialist referral for liver fibrosis, and provide an opportunity for recommending lifestyle change. However, there are uncertainties regarding service design, effectiveness of advice given, and frequency of follow-up.

Aims

To assess: a) effectiveness of standard care lifestyle advice for weight management and alcohol consumption; b) uptake for liver rescans; c) usefulness of a 4.5-year time interval of rescanning in monitoring progression of liver fibrosis.

Design and setting

Analysis of patient outcomes 4.5 years after first 'liver service' attendance that included transient elastography in five GP practices in Southampton, UK.

Methods

Outcomes included weight, alcohol consumption, rescans uptake, time interval between scans and change in liver fibrosis stage.

Results

401 participants were re-contacted. Mean±SD weight loss was 1.2kg±8.4kg ($p=0.005$), alcohol AUDIT grade increased by 7.8% ($p<0.001$). 116/401 participants were eligible for liver rescanning. 59/116 (50.9%) agreed to undergo rescanning. Mean±SD time interval between scans was 53.6±3.4 months. Liver fibrosis progressed from mild ($\geq 6.0\text{kPa}$ -8.1kPa) to significant fibrosis (8.2kPa-9.6kPa) in 3.4% of patients; from mild to advanced fibrosis (9.7kPa-13.5kPa)/cirrhosis ($\geq 13.6\text{kPa}$) in 15.3% of patients, and did not progress in 81.3%. No baseline factors were independently associated with liver fibrosis progression at follow-up.

Conclusion

Rescan recall attendance and adherence to lifestyle changes needs improving. Optimum time interval between scans remains uncertain. After a mean interval of 53.6 months between scans, and with no specific predictors indicated, a substantial minority (18.7%) experienced a deterioration in fibrosis grade.

Keywords

Primary care, screening, early diagnosis, risk reduction behaviour, liver disease.

How this fits in

Being overweight/obese and drinking above the recommended weekly units of alcohol are two of the main risk factors for the development and progression of liver disease. Losing weight and/or drinking less alcohol will improve liver health as well as overall health. Transient elastography is being used in primary care to scan patients and identify liver fibrosis/cirrhosis. However, patient uptake for liver rescanning, the ideal time interval for a follow-up liver rescan to enable identification of progressive liver fibrosis, and the effectiveness of standard care advice for weight management and alcohol consumption, are all uncertain. Our aims were to assess whether standard care advice to lose weight and reduce alcohol consumption was effective in: a) restoring and maintaining ideal body weight, b) moderating alcohol consumption. Additionally, we aimed to determine what proportion of participants would experience a progression in liver fibrosis stage at follow-up liver scan.

Introduction

The estimated annual cost of liver disease is £5.24 billion,¹ and is the third biggest cause of premature mortality.² The principal cause of liver disease is excess alcohol consumption,³ however, 30% of the UK population have non-alcoholic fatty liver disease (NAFLD),⁴ which is often undiagnosed,² and can progress to cirrhosis, liver failure or liver cancer, poor quality of life, and death.¹ Liver disease places a huge burden on the NHS in terms of costs and resource utilisation, both of which are predicted to increase.^{1,5} Besides increasing risk of liver morbidity and mortality, NAFLD is a multisystem disease⁶ that also increases risk of extra-hepatic diseases such as cancer, type 2 diabetes (T2DM), cardiovascular disease, and chronic kidney disease).^{7,8}

Around three-quarters of patients with cirrhosis remain undetected until they present as an emergency with the complication of advanced liver disease, only one-third survive in the long term.^{2,3,9} Detection of liver disease is difficult because it progresses silently with no signs or symptoms until liver failure develops¹⁰ and the opportunity for intervention is missed. In 2020 the National Institute for Clinical Excellence recommended the use of vibration-controlled transient elastography¹¹ (VCTE) for assessing liver fibrosis and cirrhosis in primary care.¹²

Local care and treatment of liver disease (LOCATE) was a large feasibility trial that embedded specialist liver nurses into General Practitioner surgeries.¹³ The primary objective of LOCATE was to evaluate whether using the combined results of VCTE and liver fibrosis markers¹⁴ would, when compared with usual care, improve the identification of liver fibrosis.

Secondary to identifying liver disease within the community, the LOCATE intervention also provided patients with a brief behavioural intervention (BI) at the time of their liver health assessment. The BI was delivered by specialist liver nurses who would inform patients of their VCTE reading (**Supplementary Box 1**), and offer appropriate lifestyle changes regarding weight management (**Supplementary Box 2**) and alcohol consumption (**Supplementary Box 3**).

Aims

To report on an 'at risk' group of patients managed solely in primary care:

1. Whether the standard care advice to lose weight and drink within UK alcohol unit guidance was effective after 4.5 years.
2. Uptake for a liver rescan after 4.5 years.
3. Whether the time interval of 4.5 years between liver scans is effective in monitoring the progression of liver fibrosis and to report the change in liver fibrosis stage between baseline and follow-up scans.

Method

Design

This was a follow-up study after the LOCATE intervention. The study design and methods of the LOCATE intervention have been reported previously.¹³ **Figure 1** shows the flow of participants.

Measurable outcomes:

1. Change in alcohol AUDIT grade between baseline and follow-up using the World Health Organisation Alcohol Use Disorders Identification Test (AUDIT) questionnaire.^{15 16}
2. Change in weight (kg) between baseline and follow-up.
3. Uptake of patients attending for liver rescanning.
4. Change in liver fibrosis between baseline and follow-up, measured using VCTE.
5. The proportion of patients whose liver fibrosis stage has progressed between baseline and follow-up.

Procedure

The LOCATE database of patients ($n=910$) was screened to exclude deceased patients ($n=15$) and patients who had declined to be contacted for follow-up ($n=110$). The remaining patients ($n=785$) were telephoned between August 2019 and May 2020 and invited to take part in the follow-up. Patients who agreed to take part ($n=401$) were asked to report their current weight and answer alcohol AUDIT questions.

After the weight and alcohol AUDIT follow-up, all eligible patients were invited for a repeat liver scan using the parameters below:

Exclusion criteria (Supplementary Box 4)

Patients whose baseline VCTE readings were $<6.0\text{kPa}$ ($n=282$) and $\geq 12.0\text{kPa}$ ($n=17$).

Inclusion criteria (Supplementary Box 5)

Patients with a baseline VCTE reading of ≥ 6.0 kPa and < 12.0 kPa ($n=116$).

Two recruitment methods were used to invite patients for a rescan:

1. The study team wrote to the GPs of all patients eligible for a rescan to ask them to refer their patients to the community liver service (**Supplementary Box 6**).
2. The study team also telephoned all eligible patients directly to invite them for a rescan.

Rescans took place at two primary care sites in Southampton. The FibroScan Mini+430 and 402 models were used. All patients who had a rescan were informed of their follow-up reading and how it compared to their baseline scan. All patients, except one, consented for their GP to be advised of the repeat liver scan reading (**Supplementary Box 7**). Patients whose follow-up VCTE reading was > 10.0 kPa were referred to a secondary care Hepatology clinic as per the locally agreed referral pathway.¹⁷

Analysis

The alcohol AUDIT scores, weight of patients and VCTE readings were analysed using IBM SPSS statistics 27 software.

At the time of the LOCATE final study, validated VCTE cut-off values for each of the stages of liver fibrosis were not well established. At follow-up we used validated cut-off values from the results of large biopsy study published in 2019,¹⁸ see **Supplementary Table 3** for a comparison of cut-off values.

A 15% coefficient of variation was applied to the rescan readings to reliably identify any changes to fibrosis stage between baseline and follow-up.¹⁹ Standard descriptive statistics were used to summarise variables: mean (SD) for continuous variables or median (IQR) for skewed variables, and numbers and percentages for categorical variables. Paired samples t-tests were used to determine the mean differences between baseline and follow-up. Chi-square test for independence ($\alpha=0.05$) was used to determine the relationship between categorical variables. A two-tailed independent samples t-test was used to compare the differences between groups and a binary logistic regression analysis was used to test the relationship between the baseline independent variables and the outcome of liver fibrosis stage progression at follow-up.

Results

Mean (SD) time interval between baseline and the weight and alcohol AUDIT follow-up was 53.4 ± 3.7 months.

Baseline characteristics from patients who took part in the weight and alcohol AUDIT ($n=401$) were analysed and compared with all patients who consented to be contacted for follow-up ($n=785$). We found there were no differences in sex, ethnicity, BMI, and weight. The median (IQR) age of patients who completed the weight and alcohol AUDIT follow-up was higher than the overall cohort of patients who consented to take part in the follow-up: 52 (40–60) years and 51 (39–60) years respectively ($p=0.009$). Patients with 'high' alcohol AUDIT grades were less likely to take part in the weight and alcohol AUDIT follow-up than patients with a 'low risk' alcohol AUDIT grade ($p=0.016$). (**Supplementary Table 4**).

Baseline and follow-up characteristics of patients who took part in the weight and alcohol AUDIT questions ($n=401$) were analysed and compared. At follow-up the median (IQR) BMI was lower than at baseline, respectively: 28.0 (40-60) kg/m² and 28.1 (24.8-33.1) kg/m² ($p=0.008$). Mean (SD) weight loss was 1.2kg±8.4kg ($p=0.005$), and, when compared to baseline, patients were more likely to have a 'high' alcohol AUDIT grade than a 'low risk' alcohol AUDIT grade ($p<0.001$) (**Supplementary Table 5**).

50.8% ($n=59$) of participants eligible for a rescans ($n=116$) accepted the invitation and underwent a liver rescans (**Supplementary Table 2**). Their characteristics were analysed and compared with all patients who were eligible to take part in the rescans follow-up. We found there to be no differences in sex, ethnicity, T2DM, age, BMI, weight, fibrosis stage and alcohol AUDIT grades (**Supplementary Table 6**).

Mean (SD) time interval between baseline and follow-up scans was 53.6±3.4 months (4.5 years).

When compared to baseline there was no change to fibrosis stage at follow-up for 32.2% of patients ($n=19$) and a decrease in fibrosis stage in 49.1% of patients ($n=29$). At follow-up we found 18.7% ($n=11$) of patients had progressed their liver fibrosis stage: 3.4% ($n=2$) to F2 (8.2kPa-9.6kPa) and 15.3% ($n=9$) to F3 (9.7kPa-13.5kPa)/F4 (≥13.6kPa) (**Table 1 and Supplementary Table 7**).

Table 1: Summary of patient VCTE fibrosis stage changes between baseline and follow-up scans ($n=59$)

We compared the characteristics of patients whose liver fibrosis had progressed (progressors) with patients whose liver fibrosis had remained the same or reversed (non-progressors), and found there were trends towards increased BMI and increased proportions with T2DM amongst participants who experienced progression of their liver disease. The mean±SD change in kPa for the 'progressors' was 6.4±3.5kPa, and for the 'non-progressors' was -1.5±2.0kPa ($p=0.041$) (**Table 2**).

Table 2: Characteristics of patients who, at follow-up, had either progressed their liver fibrosis stage (Progressors) or their liver fibrosis stage had remained the same/reversed (Non-Progressors)

We undertook two separate binary logistic regression analyses to investigate whether any of the measured baseline factors were independently associated with a) the progression of liver fibrosis stage to F3 (9.7kPa-13.5kPa) or F4 (≥13.6kPa) and b) the regression/no change of liver fibrosis stage to F2 (8.2kPa - 9.6kPa) / F1 (6.0kPa - 8.1kPa) / F0 (<6.0kPa). These data showed that none of the factors were associated with either the progression or regression/no change of liver fibrosis, although it should be noted that our study lacks sufficient power to adequately test this important question. The model included T2DM, age, sex, baseline VCTE reading, baseline BMI and alcohol AUDIT grade and is shown in **Supplementary Tables 8 and 9**.

Discussion

Summary of main findings

Our results show that standard care advice regarding weight loss and alcohol consumption has, after 53.4 ± 3.4 months (mean \pm SD), had little effect on weight and alcohol consumption. In the UK being overweight and obese tends to increase with age.²⁰ Our findings suggest that the participants we followed up have arrested this trend, and lost an average of 1.2kg in body weight, since the UK data suggest our participants should have gained an average of 1.6kg during the period of follow up. Thus, with the important caveat that we did not have a control group, it is possible to interpret our data, as subjects having achieved a mean nett weight loss of 2.8kg during the study (see **Figure 2**). That said, although weight gain has been arrested, weight loss of 1.2kg or 1.4% is very small, and such a small percentage weight loss is of questionable clinical significance for improving liver disease.

There was a limited response to the invitation for a rescans (50.9%), and evidence of advanced progression of liver disease after 53.6 ± 3.4 months (Mean \pm SD) was identified in 15.3% of patients whose fibrosis stage had progressed from F1 (6.0kPa-8.1kPa)/F2 (8.2kPa-9.6kPa) to F3 (9.7kPa-13.5kPa)/F4 (≥ 13.6 kPa). None of the baseline factors were independently associated with progression to F3 (9.7kPa-13.5kPa) or F4 (≥ 13.6 kPa) fibrosis.

Strengths and limitations

To our knowledge, this is the first study based in primary care that has used VCTE to follow-up on patients who were determined on baseline scanning to be 'at risk' of progression of liver fibrosis. We show that a single simple intervention with standard care advice regarding weight management and alcohol consumption did not have a substantial effect on weight management or alcohol consumption after 53.4 months. Additionally, we have provided estimates of likely progression of liver disease in primary care patients whose liver disease was not deemed to be sufficiently severe to warrant referral to the secondary care Hepatology service. In those patients consenting to a rescans after 53.6 months, our data show that there was progression of liver disease in 15.3% of patients whose fibrosis stage had progressed from mild/significant fibrosis (F1 (6.0kPa-8.1kPa)/F2 (8.2kPa-9.6kPa)) to advanced fibrosis/cirrhosis (F3 (9.7kPa-13.5kPa) /F4 (≥ 13.6 kPa)), indicating that there is a need for establishing a rescans service more widely in primary care, and there is a need to better identify those individuals at baseline in this setting who are at risk of liver fibrosis progression.

Limitations of this study include: the loss to follow-up was disappointing; the follow-up data was collected during the COVID-19 pandemic that included intermittent periods of restriction on movement in the UK. It is possible that there is regression to the mean with repeat scanning, however, our inclusion criteria for rescanning did not include subjects at the extreme ends of the distribution curve (only subjects with baseline scan results of ≥ 6.0 kPa and < 12.0 kPa were included). Thus the effect of regression to the mean in this cohort is likely to be small. Additionally, our follow-up cohort was a predominantly a White ethnic group; we were unable to verify the T2DM status for a significant number of the patients who took part in the weight and alcohol AUDIT follow-up and, patients self-reported their weight.

Comparison with existing literature

Patient adherence to lifestyle-based interventions is often poor and presents a significant challenge.²¹ Current evidence indicates that lifestyle modifications to lose weight will improve liver health,²²⁻²⁴ yet we have shown that current standard care lifestyle advice does not lead to persistent change. A recommendation would be to provide healthcare professionals with additional resources, such as behavioural strategies that have been demonstrated to improve patient adherence to lifestyle changes. e.g.: self-monitoring²⁵ (where participants keep a record of, for example, their food/alcohol intake); treatment tailoring²⁶ (making flexible treatment recommendations for individual preferences); social support^{27 28} (include family members or offer group based support); skills training²⁹ (training participants to problem solve); extended care²⁵ (long term contact maintained).

Other health screening services (e.g. bowel) have found that patients of low social economic status (SES) are less likely to participate.³⁰ To address this we would recommend that GPs are given the support to promote awareness and knowledge of liver disease,^{31 32} particularly in low SES settings and in patients with obesity or T2DM,³³ and better educational resources are made available to patients.³⁴ There is limited evidence at present regarding the prognosis of those identified with liver disease in the community, our study adds to the evidence base.

Implications for research and practice

This study found that, unsurprisingly, further support is required to help patients make lifestyle changes. With additional resources, primary care can play an important role in helping patients to make positive sustainable lifestyle changes, this does not have to increase the workload of primary care physicians. In Southampton we have a community liver service for GPs to refer patients to if they suspect they may have liver disease. This service is funded by the CCG and, at the time of the liver assessment, patients have a 20-minute discussion focussed on behaviour change where potential lifestyle changes are discussed. Losing weight and drinking within UK guidelines are not just recommended to improve liver health, they will also lower the risk factors associated with malignancy, T2DM and coronary heart disease, and chronic kidney disease.^{6 35}

Any commissioning team considering implementing a liver screening service in primary care to identify liver disease should look at developing effective strategies to improve uptake, such as better educational resources for patients,³⁶ GP endorsement and personalised reminders for non-participants.³²

Importantly this study has highlighted that patients identified with intermediate fibrosis levels in community screening programs are at moderate risk of progression and robust follow-up and engagement is needed to maintain contact. If there are no specific factors (e.g. continued high alcohol consumption) that suggest patients will rapidly progress from mild fibrosis to advanced fibrosis/cirrhosis; in our opinion, the recommendation should be to manage patients on the basis that their liver disease will progress to advanced fibrosis/cirrhosis.

Ethics

This study was reviewed and approved by NRES Committee South Central—Hampshire A, Bristol Research Ethics Committee Centre, level 3, block B, Whitefriars, Lewins Mead Bristol BS1 2NT. Trial registration number: 13/SC/0012; Post-results.

Competing interests

The authors have declared no competing interests.

Acknowledgments

CDB is supported in part by the Southampton NIHR Biomedical Research Centre (IS-BRC-20004), UK). The authors would like to thank all participants for taking the time to contribute to this study; Nick Sheron for his contribution to the original LOCATE study; Shirley Health Partnership for hosting the VCTE liver rescans; Lucie Lleshi, NHS Southampton CCG, for helping combine the LOCATE patient VCTE rescan study into the newly commissioned VCTE service, and Derek Fountain and Agnès Martin for reviewing and revising the manuscript for grammar and syntax.

This research was funded by the British Liver Trust and Solent NHS Trust.

Accepted Manuscript - BJGP Open - BJGP2021.0145

References

1. Younossi ZM, Henry L. Economic and quality-of-life implications of non-alcoholic fatty liver disease. *Pharmacoeconomics* 2015; 33(12):1245-53, doi:10.1007/s40273-015-0316-5.
2. Williams R, Aspinall R, Bellis M, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. *Lancet* 2014; 384(9958): 1953-97.
3. PHE. The 2nd Atlas of variation risk factors and healthcare for liver disease in England 2017. https://fingertips.phe.org.uk/documents/FINAL_LiverAtlas.pdf (accessed 20 September 2021).
4. NHS. Non-alcoholic fatty liver disease (NAFLD) 2019. <https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/> (accessed 17 September 2021).
5. O'Hara J, Finnegan A, Dhillon H, et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. *JHEP Rep* 2015; 2(5):100142, doi:10.1016/j.jhepr.2020.100142.
6. Byrne CD, Targher G. NAFLD: A multisystem disease. *J Hepatol* 2015; 62(1 Suppl):S47-64, doi:10.1016/j.jhep.2014.12.012.
7. Armstrong MJ, Adams LA, Canbay A, et al. Extrahepatic complications of nonalcoholic fatty liver disease. *Hepatology* 2014; 59(3):1174-97, doi:10.1002/hep.26717.
8. Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. *J Hepatol* 2020; 72(4): 785-801, doi:10.1016/j.jhep.2020.01.013.
9. Gov.uk. Palliative and end of life care 2019. <https://www.gov.uk/government/collections/palliative-and-end-of-life-care> (accessed 20 September 2021).
10. Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests. *Gut* 2018; 67:6-19, doi:10.1136/gutjnl-2017-314924.
11. Echosens. FibroScan the first non-invasive medical device dedicated to chronic liver disease 2014. <http://fr.zone-secure.net/56337/890823/#page=4> (accessed 20 September 2021).
12. NICE. FibroScan for assessing liver fibrosis and cirrhosis in primary care 2020. <https://www.nice.org.uk/advice/mib216/chapter/Summary> (accessed 20 September 2021).
13. El-Gohary M, Moore M, Roderick P, et al. Local care and treatment of liver disease (LOCATE) - A cluster-randomized feasibility study to discover, assess and manage early liver disease in primary care. *PLoS One* 2018; 13(12):e0208798, doi:10.1371/journal.pone.0208798.
14. Sheron N, Moore M, Ansett S, et al. Developing a 'traffic light' test with potential for rational early diagnosis of liver fibrosis and cirrhosis in the community. *Br J Gen Pract* 2012; 62(602):e616-24, doi:10.3399/bjgp12X654588.
15. WHO. AUDIT: the alcohol use disorders identification test: guidelines for use in primary health care 2001. <https://apps.who.int/iris/handle/10665/67205> (accessed 20 September 2021).
16. Saunders JB, Aasland OG, Babor TF, et al. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II. *Addiction* 1993; 88(6):791-804, doi:10.1111/j.1360-0443.1993.tb02093.
17. Patel J, Mathews M. Liver guidance (primary care): Southampton city clinical commissioning group 2019. [https://www.stmaryssurgery.nhs.uk/media/content/files/LiverGuidance\(Primary%20Care\)STN1754.pdf](https://www.stmaryssurgery.nhs.uk/media/content/files/LiverGuidance(Primary%20Care)STN1754.pdf) (accessed 20 September 2021).
18. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. *Gastroenterology* 2019; 156(6):171730, doi:10.1053/j.gastro.2019.01.042.
19. Petta S, Sebastiani G, Viganò M, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and


- compensated advanced chronic liver disease. *Clin Gastroenterol Hepatol* 2021; 19(4): 806-815.e5, doi:10.1016/j.cgh.2020.06.045.
20. PHE. Excess Weight and COVID-19: insights from new evidence 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/907966/PHE_insight_Excess_weight_and_COVID-19_FINAL.pdf (accessed 20 September 2021).
 21. Middleton KR, Anton SD, Perri MG. Long-term adherence to health behaviour change. *Am J Lifestyle Med* 2013; 7(6):395-404, doi:10.1177/1559827613488867.
 22. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. *J Hepatol* 2012; 56(1):255-66, doi:10.1016/j.jhep.2011.06.010.
 23. Katsagoni CN, Georgoulis M, Papatheodoridis GV, et al. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. *Metabolism* 2017; 68:119-132. doi:10.1016/j.metabol.2016.12.006.
 24. Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. *J Hepatol* 2017; 67(4):829-846, doi:10.1016/j.jhep.2017.05.016.
 25. Middleton KM, Patidar SM, Perri MG. The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis. *Obes Rev* 2012; 13(6):509-17, doi:10.1111/j.1467-789X.2011.00972.x.
 26. Perri MG, Anton SD, Durning PE, et al. Adherence to exercise prescriptions: effects of prescribing moderate versus higher levels of intensity and frequency. *Health Psychol* 2002; 21(5): 452-458.
 27. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. *Health Technol Assess* 2004; 8(21):iii-iv, 1-182, doi: 10.3310/hta8210.
 28. Renjilian DA, Perri MG, Nezu AM, et al. Individual versus group therapy for obesity: effects of matching participants to their treatment preferences. *J Consult Clin Psychol* 2001; 69(4): 717-721, doi:10.1037/0022-006X.69.4.717.
 29. Perri M, Nezu AM, McKelvey WF, et al. Relapse prevention training and problem-solving therapy in the longer-term management of obesity. *J Consult Clin Psychol* 2001; 69(4):722-26.
 30. von Wagner C, Good A, Wright D, et al. Inequalities in colorectal cancer screening participation in the first round of the national screening programme in England. *Br J Cancer* 2009; 101:S60-S63, doi: 10.1038/sj.bjc.6605392.
 31. Standing HC, Jarvis H, Orr J, et al. GPs' experiences and perceptions of early detection of liver disease: a qualitative study in primary care. *Br J Gen Pract* 2018; 68(676):e743-e749, doi: 10.3399/bjgp18X699377.
 32. Duffy SW, Myles JP, Maroni R, et al. Rapid review of evaluation of interventions to improve participation in cancer screening services. *J Med Screen* 2017; 24(3):127-145, doi: 10.1177/0969141316664757.
 33. Bann D, Johnson W, Li L, et al. Socioeconomic Inequalities in body mass index across adulthood: coordinated analyses of individual participant data from three British birth cohort studies initiated in 1946, 1958 and 1970. *PLoS Med* 2017; 14(1):e1002214, doi:10.1371/journal.pmed.1002214.
 34. Agide FD, Garmaroudi G, Sadeghi R, et al. A systematic review of the effectiveness of health education interventions to increase cervical cancer screening uptake. *Eur J Public Health* 2018; 28(6):1156-1162. doi:10.1093/eurpub/cky197.
 35. Johnston MP, Patel J, Byrne CD. Diabetes is associated with increased risk of hepatocellular carcinoma in non-alcoholic steatohepatitis with cirrhosis—implications for surveillance and future pharmacotherapy. *Hepatobiliary Surg Nutr* 2020; 9(2):230-234, doi: 10.21037/hbsn.2019.10.09.
 36. Hewitson P, Ward AM, Heneghan C, et al. Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial. *Br J Cancer* 2011; 105(4):475-480, doi: 10.1038/bjc.2011.255.

Figure 1: Flow of participants through the LOCATE follow-up study.

Figure 2: Comparison of the distribution of participants' weight at baseline, follow-up and 'expected' follow-up weight (calculated from the weight gain per annum observed in recent (2020) PHE data)²⁰.

Accepted Manuscript - BJGP Open - BJGPO.2021.0145


Figure 2: Comparison of the distribution of participants' weight at baseline, follow-up and 'expected' follow-up weight (calculated from the weight gain per annum observed in recent (2020) PHE data)²⁰



Accepted Manuscript

BJGPO.2021.0175

Figure 1: Flow of participants through the LOCATE follow-up study



Accepted Manuscript
 Open - BJGPO.2021.0145

Table 2: Characteristics of patients who, at follow-up, had either progressed their liver fibrosis stage (Progressors) or their liver fibrosis stage had remained the same/reversed (Non-Progressors)

Characteristics	Progressors (n=11, 18.7%)		Non-Progressors (n=48, 81.3%)		p-value
Sex (males) (n, %)	6	54.5	32	66.7	0.478*
Age (years) (median, IQR)	58	48 - 67	57	51 - 65	0.917*
Ethnicity (BAME) (n, %)	2	18.2	8	16.7	0.927*
T2DM (positive) (n, %)	9	81.8	25	52.1	0.083*
Fibroscan readings:					
Baseline (kPa) (mean, SD)	7.2	0.8	7.7	1.7	0.024*
Follow-up (kPa) (mean, SD)	13.6	3.8	6.1	1.9	0.007*
Change in kPa between baseline and follow-up (mean, SD)	6.4	3.5	-1.5	2.0	0.041*
BMI (kg/m ²)					
Baseline (median, IQR)	33.6	28.5 - 39.4	32.0	27.5 - 35.4	0.189*
Follow-up (median, IQR)	33.3	28.7 - 37.3	30.5	26.3 - 36.6	0.706*
Time interval between scans (months) (mean, SD)	52.5	2.9	53.9	3.4	0.164*
Alcohol AUDIT grade:#					
Baseline (high) (n, %) [‡]	2	18.2	16	34.0	0.287*
Follow-up (high) (n, %) [‡]	4	36.4	18	38.3	0.866*

*p-values refer to a two-tailed independent samples t-test using a CI of 95%.

*p-values refer to a Chi-square test for independence using an alpha level of 5%.

#Two patients are excluded from the alcohol AUDIT grade change as they declined to complete the questionnaire at follow-up.

[‡]High = hazardous, harmful and dependent alcohol AUDIT grades.

Accepted Manuscript - BJGPO

Table 1: Summary of patient VCTE fibrosis stage changes between baseline and follow-up scans (n=59)

Change in fibrosis stage			
Significant change (F1 to F2)* (n, %) *6.0kPa-8.1kPa to 8.2kPa-9.6kPa	2	3.4	Progressors (n=11, 18.7%)
Advanced change (F1/F2/F3 to F3/F4)# (n, %) #6.0kPa-8.1kPa/8.2kPa-9.6kPa/9.7kPa-13.5kPa to (9.7kPa-13.5kPa/≥13.6kPa	9	15.3	
No change (n, %)	19	32.2	Non-Progressors (n=48, 81.3%)
Decrease (n, %)	29	49.1	

Accepted Manuscript - BJGP Open - BJGPO